13.77
1.85%
+0.25
Tourmaline Bio Inc stock is currently priced at $13.77, with a 24-hour trading volume of 251.00K.
It has seen a +1.85% increased in the last 24 hours and a -13.01% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $13.57 pivot point. If it approaches the $13.99 resistance level, significant changes may occur.
Previous Close:
$13.52
Open:
$13.61
24h Volume:
251.00K
Market Cap:
$353.15M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
-89.01
EPS:
-0.1547
Net Cash Flow:
$-19.23M
1W Performance:
+2.38%
1M Performance:
-13.01%
6M Performance:
-26.56%
1Y Performance:
+0.00%
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
-
Address
27 West 24th Street, Suite 702, New York
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-15-23 | Initiated | Jefferies | Buy |
Dec-04-23 | Resumed | H.C. Wainwright | Buy |
Nov-17-23 | Initiated | Truist | Buy |
Oct-31-23 | Initiated | Guggenheim | Buy |
Oct-25-23 | Initiated | Piper Sandler | Overweight |
Oct-20-22 | Initiated | H.C. Wainwright | Buy |
Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Update - MarketBeat
MarketBeat
Tourmaline Bio Inc (TRML) did well last session? – US Post News - US Post News
US Post News
Take off with Tourmaline Bio Inc (TRML): Get ready for trading – Sete News - SETE News
SETE News
Tourmaline Bio Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Nasdaq
Jump Financial LLC Buys Shares of 14500 Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Defense World
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference - ForexTV.com
ForexTV.com
Tourmaline Bio Inc Stock (TRML) Financials Data
Tourmaline Bio Inc (TRML) Net Income 2024
TRML net income (TTM) was $11.77 million for the quarter ending December 31, 2023.
Tourmaline Bio Inc (TRML) Cash Flow 2024
TRML recorded a free cash flow (TTM) of -$19.23 million for the quarter ending June 30, 2023.
Tourmaline Bio Inc (TRML) Earnings per Share 2024
TRML earnings per share (TTM) was $0.5785 for the quarter ending December 31, 2023.
Tourmaline Bio Inc Stock (TRML) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Kulkarni Sandeep Chidambar | CEO |
Nov 17 '23 |
Buy |
16.99 |
4,000 |
67,960 |
729,735 |
Thiara Parvinder | Director |
Nov 17 '23 |
Buy |
17.31 |
1,000 |
17,310 |
83,782 |
Castelein Caley | Director |
Oct 27 '23 |
Buy |
14.55 |
15,800 |
229,890 |
516,519 |
Kulkarni Sandeep Chidambar | CEO |
Oct 26 '23 |
Buy |
12.25 |
5,000 |
61,250 |
725,735 |
Castelein Caley | Director |
Oct 25 '23 |
Buy |
12.07 |
4,200 |
50,694 |
500,719 |
Thiara Parvinder | Director |
Oct 25 '23 |
Buy |
12.12 |
2,000 |
24,240 |
82,782 |
KANTOFF AARON | Director |
Oct 24 '23 |
Buy |
11.86 |
7,500 |
88,950 |
45,391 |
Thiara Parvinder | Director |
Oct 24 '23 |
Buy |
10.66 |
5,000 |
53,300 |
80,782 |
Kulkarni Sandeep Chidambar | CEO |
Oct 24 '23 |
Buy |
10.68 |
4,650 |
49,662 |
720,735 |
Ildstad Suzanne | Director |
Jun 14 '23 |
Sale |
2.49 |
12,942 |
32,244 |
3,771,392 |
About Tourmaline Bio Inc
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Cap:
|
Volume (24h):